Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 6261721, 8 pages
http://dx.doi.org/10.1155/2016/6261721
Review Article

Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer

1Department of Pathology and Diagnostics, University of Verona, 31134 Verona, Italy
2Medical Oncology Unit, Fatebenefratelli Hospital, 82100 Benevento, Italy
3Department of Experimental and Clinical Medicine “Gaetano Salvatore”, University “Magna Grecia”, 88100 Catanzaro, Italy
4Department of Sciences and Technologies, University of Sannio, 82100 Benevento, Italy

Received 30 October 2015; Revised 11 January 2016; Accepted 20 January 2016

Academic Editor: Hassan Ashktorab

Copyright © 2016 Pietro Parcesepe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Gagan and E. M. Van Allen, “Next-generation sequencing to guide cancer therapy,” Genome Medicine, vol. 7, no. 1, article 80, 2015. View at Publisher · View at Google Scholar
  2. A. Bardelli and S. Siena, “Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1254–1261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Valastyan and R. A. Weinberg, “Tumor metastasis: molecular insights and evolving paradigms,” Cell, vol. 147, no. 2, pp. 275–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. A. J. Gentles, A. M. Newman, C. L. Liu et al., “The prognostic landscape of genes and infiltrating immune cells across human cancers,” Nature Medicine, vol. 21, no. 8, pp. 938–945, 2015. View at Publisher · View at Google Scholar
  5. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. G. DeNardo, M. Johansson, and L. M. Coussens, “Immune cells as mediators of solid tumor metastasis,” Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 11–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Condeelis and J. W. Pollard, “Macrophages: obligate partners for tumor cell migration, invasion, and metastasis,” Cell, vol. 124, no. 2, pp. 263–266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Trédan, C. M. Galmarini, K. Patel, and I. F. Tannock, “Drug resistance and the solid tumor microenvironment,” Journal of the National Cancer Institute, vol. 99, no. 19, pp. 1441–1454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. I. P. Witz, “The tumor microenvironment: the making of a paradigm,” Cancer Microenvironment, vol. 2, supplement 1, pp. S9–S17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Sethi and Y. Kang, “Unravelling the complexity of metastasis—molecular understanding and targeted therapies,” Nature Reviews Cancer, vol. 11, no. 10, pp. 735–748, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. B. B. McConnell and V. W. Yang, “The role of inflammation in the pathogenesis of colorectal cancer,” Current Colorectal Cancer Reports, vol. 5, no. 2, pp. 69–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. H. A. Smith and Y. Kang, “The metastasis-promoting roles of tumor-associated immune cells,” Journal of Molecular Medicine, vol. 91, no. 4, pp. 411–429, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Kitamura, B.-Z. Qian, and J. W. Pollard, “Immune cell promotion of metastasis,” Nature Reviews Immunology, vol. 15, no. 2, pp. 73–86, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Pancione, G. Giordano, A. Remo et al., “Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis,” Journal of Immunology Research, vol. 2014, Article ID 686879, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. De Palma and C. E. Lewis, “Macrophage regulation of tumor responses to anticancer therapies,” Cancer Cell, vol. 23, no. 3, pp. 277–286, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mantovani, T. Schioppa, C. Porta, P. Allavena, and A. Sica, “Role of tumor-associated macrophages in tumor progression and invasion,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 315–322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, “Immunogenic cell death and DAMPs in cancer therapy,” Nature Reviews Cancer, vol. 12, no. 12, pp. 860–875, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Malietzis, M. Giacometti, R. H. Kennedy, T. Athanasiou, O. Aziz, and J. T. Jenkins, “The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis,” Annals of Surgical Oncology, vol. 21, no. 12, pp. 3938–3946, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. D. C. McMillan, “Systemic inflammation, nutritional status and survival in patients with cancer,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 12, no. 3, pp. 223–226, 2009. View at Publisher · View at Google Scholar
  20. D. T. Le, J. N. Uram, H. Wang et al., “PD-1 blockade in tumors with mismatch-repair deficiency,” The New England Journal of Medicine, vol. 372, no. 26, pp. 2509–2520, 2015. View at Publisher · View at Google Scholar
  21. J. Barretina, G. Caponigro, N. Stransky et al., “The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity,” Nature, vol. 483, no. 7391, pp. 603–607, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Giordano, A. Febbraro, M. Venditti et al., “Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept,” Gastroenterology Research and Practice, vol. 2014, Article ID 526178, 13 pages, 2014. View at Publisher · View at Google Scholar
  23. N. A. Giraldo, E. Becht, R. Remark, D. Damotte, C. Sautès-Fridman, and W. H. Fridman, “The immune contexture of primary and metastatic human tumours,” Current Opinion in Immunology, vol. 27, no. 1, pp. 8–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. J. P. Väyrynen, A. Tuomisto, K. Klintrup, J. Mäkelä, T. J. Karttunen, and M. J. Mäkinen, “Detailed analysis of inflammatory cell infiltration in colorectal cancer,” British Journal of Cancer, vol. 109, no. 7, pp. 1839–1847, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Donskov, “Immunomonitoring and prognostic relevance of neutrophils in clinical trials,” Seminars in Cancer Biology, vol. 23, no. 3, pp. 200–207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. A. Droeser, C. Hirt, S. Eppenberger-Castori et al., “High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor,” PLoS ONE, vol. 8, no. 5, Article ID e64814, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Tecchio, P. Scapini, G. Pizzolo, and M. A. Cassatella, “On the cytokines produced by human neutrophils in tumors,” Seminars in Cancer Biology, vol. 23, no. 3, pp. 159–170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Snyder, V. Makarov, T. Merghoub et al., “Genetic basis for clinical response to CTLA-4 blockade in melanoma,” The New England Journal of Medicine, vol. 371, no. 23, pp. 2189–2199, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Yadav, S. Jhunjhunwala, Q. T. Phung et al., “Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing,” Nature, vol. 515, no. 7528, pp. 572–576, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. S. L. Topalian, C. G. Drake, and D. M. Pardoll, “Immune checkpoint blockade: a common denominator approach to cancer therapy,” Cancer Cell, vol. 27, no. 4, pp. 450–461, 2015. View at Publisher · View at Google Scholar
  31. J. A. Joyce and J. W. Pollard, “Microenvironmental regulation of metastasis,” Nature Reviews Cancer, vol. 9, no. 4, pp. 239–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Larizza, V. Schirrmacher, and E. Pfluger, “Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage,” Journal of Experimental Medicine, vol. 160, no. 5, pp. 1579–1584, 1984. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Munzarova, L. Lauerova, and J. Capkova, “Are advanced malignant melanoma cells hybrids between melanocytes and macrophages?” Melanoma Research, vol. 2, no. 2, pp. 127–129, 1992. View at Publisher · View at Google Scholar · View at Scopus
  34. M. B. Maniecki, A. Etzerodt, B. P. Ulhøi et al., “Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells,” International Journal of Cancer, vol. 131, no. 10, pp. 2320–2331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Shabo, H. Olsson, X.-F. Sun, and J. Svanvik, “Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time,” International Journal of Cancer, vol. 125, no. 8, pp. 1826–1831, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Shabo and J. Svanvik, “Expression of macrophage antigens by tumor cells,” in Cell Fusion in Health and Disease, vol. 950 of Advances in Experimental Medicine and Biology, pp. 141–150, Springer, Dordrecht, The Netherlands, 2011. View at Publisher · View at Google Scholar
  37. G. Steinert, S. Schölch, T. Niemietz et al., “Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer,” Cancer Research, vol. 74, no. 6, pp. 1694–1704, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Grimmig, M. Kim, C.-T. Germer, M. Gasser, and A. M. Waaga-Gasser, “The role of FOXP3 in disease progression in colorectal cancer patients,” OncoImmunology, vol. 2, no. 6, Article ID e24521, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Stagg, “The double-edge sword effect of anti-CD73 cancer therapy,” OncoImmunology, vol. 1, no. 2, pp. 217–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Giordano, A. Febbraro, E. Tomaselli et al., “Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer,” Journal of Experimental & Clinical Cancer Research, vol. 34, article 108, 2015. View at Publisher · View at Google Scholar
  41. D. I. Gabrilovich, S. Ostrand-Rosenberg, and V. Bronte, “Coordinated regulation of myeloid cells by tumours,” Nature Reviews Immunology, vol. 12, no. 4, pp. 253–268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Sun, S. Hobor, A. Bertotti et al., “Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3,” Cell Reports, vol. 7, no. 1, pp. 86–93, 2014. View at Publisher · View at Google Scholar · View at Scopus